ABSTRACT: Lymphotoxin beta receptor (LTBR), a member of TNFRSF, was identified as a key regulator in the development, organization, and homeostasis of lymphoid tissues (Wolf, Seleznik, Zeller, & Heikenwalder, 2010). Recently, LTBR has been shown to play a role in tumor biology, both in solid tumors and in hematological cancers (Fernandes et al., 2016; Haybaeck et al., 2009; Lo et al., 2007). However, the role of LTBR in cancer biology is still controversial. From the perspective of tumor eradication, the combination of LIGHT and IFN-g can induce apoptotic cell death in HT29 cells and some other cell lines via the increase of intracellular reactive oxygen species (ROS) (Chang, Chao, Hsieh, & Lin, 2004; Zhang, Liu, Demchik, Zhai, & Yang, 2004). Artificial LTBR agonist was shown to induce tumor necrosis and decrease tumor burden in vivo in colon cancer or melanoma. (Hu et al., 2013), while recent studies revealed that LTBR mediated tumor progression, triggered by either LTα1b2 or LIGHT stimulation, leads to the recruitment of more infiltrating immune cells and the secretion of pro-survival inflammatory cyto-/chemokines (Ware, 2005). From this, the aim of the project is to compare the signalling changes between WT cells and HOIP absent Hep3B cells using a moTAP tagged LIGHT ligand. This ligand was pulled down by Flag IP, followed by Strep-tactin IP to explore the LTBR signalling complex with and without LUBAC. The result from this experiment would provide an unbiased picture of components of the LTBR-SC, also pointing out the differences between canonical NF-kB pathway and noncanonical Nf-kB pathway.